Prevalence of depression and anxiety in patients requesting physicians’ aid in dying: cross sectional survey

Linda Ganzini, Elizabeth R Goy and Steven K Dobscha

BMJ 2008;337:a1682
doi:10.1136/bmj.a1682

Updated information and services can be found at:
http://bmj.com/cgi/content/full/337/oct07_2/a1682

These include:

References
This article cites 34 articles, 16 of which can be accessed free at:
http://bmj.com/cgi/content/full/337/oct07_2/a1682#BIBL

1 online articles that cite this article can be accessed at:
http://bmj.com/cgi/content/full/337/oct07_2/a1682#otherarticles

Rapid responses
5 rapid responses have been posted to this article, which you can access for free at:
http://bmj.com/cgi/content/full/337/oct07_2/a1682#responses

You can respond to this article at:
http://bmj.com/cgi/eletter-submit/337/oct07_2/a1682

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top left of the article

Topic collections
Articles on similar topics can be found in the following collections

Motor neurone disease (49 articles)
Neuromuscular disease (768 articles)
Spinal cord (362 articles)
Mood disorders (including depression) (591 articles)

Notes

To order reprints follow the "Request Permissions" link in the navigation box
To subscribe to BMJ go to:
http://resources.bmj.com/bmj/subscribers
Prevalence of depression and anxiety in patients requesting physicians’ aid in dying: cross sectional survey

Linda Ganzini, professor,1,2 Elizabeth R Goy, assistant professor,1,2 Steven K Dobscha, associate professor1,2

ABSTRACT

Objective To determine the prevalence of depression and anxiety in terminally ill patients pursuing aid in dying from physicians.

Design Cross sectional survey.

Setting State of Oregon, USA.

Participants 58 Oregonians, most terminally ill with cancer or amyotrophic lateral sclerosis, who had either requested aid in dying from a physician or contacted an aid in dying advocacy organisation.

Main outcome measures Diagnosis of depression or anxiety according to the hospital anxiety and depression scale and the structured clinical interview for the Diagnostic and Statistical Manual of Mental Disorders.

Results 15 study participants met “caseness” criteria for depression, and 13 met criteria for anxiety. 42 patients died by the end of the study; 18 received a prescription for a lethal drug under the Death with Dignity Act, and nine died by lethal ingestion. 15 participants who received a prescription for a lethal drug did not meet criteria for depression; three did. All three depressed participants died by legal ingestion within two months of the research interview.

Conclusion Although most terminally ill Oregonians who receive aid in dying do not have depressive disorders, the current practice of the Death with Dignity Act may fail to protect some patients whose choices are influenced by depression from receiving a prescription for a lethal drug.

INTRODUCTION

In 1994 the voters of Oregon passed the Death with Dignity Act, which legalised the practice of physicians’ aid in dying for terminally ill patients. This law authorises a physician to prescribe a lethal dosage of drug, usually a short acting barbiturate, to a competent, requesting patient for the purposes of self administration.1 Several safeguards in the law ensure that patients are adult, competent, terminally ill, and choosing to end life voluntarily but not impulsively (box). Since enactment of the law in 1997, between one and two out of every thousand deaths in Oregon has been by lethal ingestion.1

The extent to which potentially treatable psychiatric disorders may influence patients’ decisions for aid in dying has been debated. For people at the end of life, depression, hopelessness, and psychosocial distress are among the strongest correlates of desire for hastened death.2-9 Eighty per cent of patients with cancer who complete suicide have a mood disorder, and, in primary care populations, treatment of depression reduces suicidal ideation.10-14 The Death with Dignity Act requires that if the prescribing or consulting physician is concerned that the patient’s judgment is impaired by a mental disorder (such as depression) the patient must be referred to a psychiatrist or a psychologist. No drug can be prescribed until the mental health professional determines that the patient does not have a mental disorder causing impaired judgment.1 Physicians, hospice professionals, and family members of patients in Oregon who pursue aid in dying generally do not believe that depression influences choices for hastened death.15,16 In 2007 none of the people who died by lethal ingestion in Oregon had been evaluated by a psychiatrist or a psychologist.1 Healthcare professionals, however, often fail to recognise depression, particularly among medically ill patients.17-20 The goal of this study was to determine the prevalence and severity of psychological distress, including major depressive disorder, in Oregonians who request aid in dying.

METHODS

We used several sources to notify patients of the opportunity to participate in our study. Some potential participants had contacted Compassion and Choices of Oregon for information about accessing aid in dying. Compassion and Choices is an organisation that offers information and assistance to people who choose aid in dying in Oregon. In 2006 Compassion and Choices gave information to or attended the deaths of three quarters of patients who chose aid in dying.21 Other potential participants made an explicit request for aid in dying to a physician as outlined in the Death with Dignity Act. Ethics consultants and palliative medicine and oncology specialists in northwest Oregon invited these patients to participate. Patients referred from all sources contacted study personnel directly for more information about enrolling. All patients gave written informed consent to participate.

The study psychologist (ERG) administered all MMCI interviews to participants. The second study psychologist (SA) administered all MADRS assessments. The study statistician (SKD) implemented all data analyses. The first author (LG) provided the study’s study design and interpretation of findings.

Participants

We included all Oregonians who request aid in dying from a physician or contact an aid in dying advocacy organisation. We excluded patients with severe cognitive impairment, since the ability to provide informed consent is essential for participation in this study. Some participants had previously been evaluated by a psychiatrist or psychologist for the purposes of self administration. 6 participants had been evaluated by a psychiatrist or psychologist for the purposes of self administration, but did not meet criteria for depression. 2 participants had been evaluated by a psychiatrist or psychologist for the purposes of self administration, but did not meet criteria for anxiety.

Participants had received a prescription for a lethal drug under the Death with Dignity Act, or died by lethal ingestion. 18 study participants met criteria for depression, and 13 met criteria for anxiety.

RESULTS

58 study participants met “caseness” criteria for depression, and 13 met criteria for anxiety. 42 patients died by the end of the study; 18 received a prescription for a lethal drug under the Death with Dignity Act, and nine died by lethal ingestion. 15 participants who received a prescription for a lethal drug did not meet criteria for depression; three did. All three depressed participants died by legal ingestion within two months of the research interview.

Conclusion

Although most terminally ill Oregonians who receive aid in dying do not have depressive disorders, the current practice of the Death with Dignity Act may fail to protect some patients whose choices are influenced by depression from receiving a prescription for a lethal drug.
Legal requirements of the Oregon Death with Dignity Act¹

The attending physician who is responsible for care of the patient’s terminal illness must ensure that:

- The patient is aged 18 years or above
- The patient is a resident of the state of Oregon
- The patient has made one written and two oral requests separated by 15 days
- The patient understands the risks of aid in dying and the alternatives, including hospice and comfort care
- The patient is assessed by a consulting physician
- Information about the patient is reported to the Oregon Department of Human Services

The attending and consulting physicians must ensure that:

- The patient is capable of making and communicating healthcare decisions
- The decision is voluntary
- The patient has a terminal illness that would, within reasonable medical judgment, cause death within six months
- The patient is referred to a psychologist or psychiatrist if concern exists that the patient has a psychiatric disorder including depression that may impair judgment

Information from statistical reports are compiled by the Oregon Department of Human Services and published yearly¹

MacArthur competence assessment tool to determine participants’ capacity to consent to research.²² Once enrolled, participants confirmed that they had expressed interest in obtaining aid in dying through Compassion and Choices or explicitly requested aid in dying from a physician. The protocol required exclusion of participants with cognitive impairment (23 or less on the Folstein McHugh mini-mental state examination or 7 or less on the short portable mental status questionnaire²³)²⁵. The psychologist administered the hospital anxiety and depression scale,²⁶ which includes seven depression items and seven anxiety items, each rated on a 0–3 scale. For the purposes of identifying cases and consistent with expert recommendations, we identified participants with hospital anxiety and depression scale depression scores of 11 or greater as “depressed” and those with anxiety scores of 10 or greater as “anxious.”²⁷ The psychologist administered the 20 item Beck hopelessness scale,²⁸ a well validated measure of hopelessness, which is a predictor of suicidal ideation and suicide attempts.²⁹ ³⁰ We designated those with scores of 10 or greater as “hopeless.”

The psychologist completed the current mood disorder section of the structured clinical interview for American Psychiatric Association Diagnostic and Statistical Manual-IV axis I disorders (SCID-I), a standard research instrument for diagnosing mental disorders.³¹ Because knowing that the patient has requested aid in dying may influence diagnostic thresholds for depression, the SCID interview was audiotaped and the tapes were reviewed by a research psychiatrist (SKD) who did not know if the patient had requested aid in dying (19 audiotapes from terminally ill patients who had not requested aid in dying were randomly interspersed). Based on studies by Chochinov and colleagues,³² the severity of depressed mood or anhedonia needed to be at least moderate for the two weeks before the interview in order to reach the threshold for diagnosis. Chochinov et al also reported that when moderate thresholds were used for mood criteria, presence or absence of physical symptoms (such as weight loss or fatigue) no longer influenced categorisation of depression. Using an inclusive approach, we attributed all physical symptoms of depression to the diagnosis of depression, even if they might be a result of terminal disease. Thoughts of death or suicide and suicidal plans or attempts are criteria for major depressive disorder in the American Psychiatric Association Diagnostic and Statistical Manual. ³¹ We attributed suicidal ideation to a diagnosis of depression only if the patient endorsed suicidal thoughts or plans aside from aid in dying. The final SCID diagnosis of major depressive disorder was reached by consensus if ERG and SKD disagreed. For the purposes of identifying cases of depression, we considered participants to be depressed if their SCID was positive or their hospital anxiety and depression scale depression score was 11 or greater.²⁷

Participants rated their overall suffering in the two weeks before the interview on an 11 point scale with end points labelled 0=“I have not suffered” and 10=“I have suffered severely.”³³ They rated their quality of life in the previous two weeks on an 11 point scale with 0=“Quality of life as good as it can be” and 10=“Terrible, very bad quality of life.” Participants rated their desire for death in the two weeks preceding the interview on an 11 point scale with end points labelled 0=“I desire to live as long as possible” and 10=“I have a strong desire to die soon.” Participants rated the influence of depression as a reason for requesting aid in dying on a scale on which 1=“depression not at all important in the decision to request a lethal prescription” and 5=“depression very important in the decision to request a lethal prescription.”

All participants diagnosed with major depressive disorder were notified of this result at the time of the study visit, and the study psychologist recommended treatment and offered to facilitate counselling. As is standard at our institution, a safety plan was developed so that all patients who seemed upset by participation in the study or were found to be imminently suicidal by means other than legalised assisted dying would be referred for an evaluation of mental health. Otherwise, participants were assured confidentiality in order to facilitate honest disclosure. We obtained information on outcomes—whether the study participant received a prescription of a lethal drug or died by lethal ingestion—six months or more after all other data collection was complete.

Data analysis

We present data as frequencies and proportions for categorical items and as means and standard deviations for normally distributed continuous items. We used Student’s  ᵃ  test to compare means. All tests were two tailed and α was set at 0.05.
RESULTS
Of 178 Compassion and Choices clients notified of the opportunity to participate in the study, 12 were ineligible or deceased and 47 (28%) enrolled. The other 11 participants were refused from clinicians at other medical centres. No patients were excluded because of cognitive impairment or lack of capacity to consent to research. The mean age of the 58 patients requesting aid in dying was 66 (SD 12) years. Thirty one participants were women, 22 were married, and 21 were enrolled in a hospice at the time of the interview. The most common terminal diseases were cancer (n=44) and amyotrophic lateral sclerosis (n=7). At the time of the study interview 46 patients had explicitly requested aid in dying from a physician and 47 had contacted Compassion and Choices to obtain aid in dying.

Eight participants scored 11 or higher on the hospital anxiety and depression scale for depression, 13 scored 10 or greater on the anxiety subscale, and 11 scored 10 or higher on the Beck hopelessness scale. Twelve participants were diagnosed with depression by the SCID. Fifteen participants met our criteria for depression by being depressed on the SCID or having a hospital anxiety and depression scale depression score of 11 or higher. The mean desire to die among depressed participants was 5.7 (SD 3.0) on our 11 point scale. Seven of the depressed group did not attribute their pursuit of aid in dying to depression at all (score=1), but six felt that depression somewhat or strongly influenced their preference for hastened death (scores=3, 4, or 5). An offer to facilitate counselling was made to all depressed patients, but only one participant (patient C below) agreed.

Among the 42 participants who died by the end of the study, 18 received a prescription for a lethal drug and nine died by lethal ingestion. Among decedents, no significant differences existed between those who received a prescription for a lethal drug and those who did not on measures of psychosocial distress, except that those who received a prescription had (surprisingly) a lower desire to die and a trend toward lower hopelessness scores (table 1).

Three of the 18 participants who received a prescription for a lethal drug met our criteria for depression on either the SCID or hospital anxiety and depression scale (table 2), and 15 did not. All three died by lethal ingestion in their home within two months of the interview. None had been evaluated by a mental health professional before participation in the research. Patient A, an elderly man with cancer who was receiving home hospice services, met “caseness” criteria on the hospital anxiety and depression scale with a depression score of 12, although his SCID result was negative. Patient B, a middle aged woman with cancer who was receiving home hospice services, was depressed by SCID criteria. She declined to complete the hopelessness scale because she had “trouble with the entire concept of hope.” She rated her desire to die and her suffering as quite high. Whether patients A and B received mental health evaluation or treatment after participation in the study is unknown. Patient C, an elderly woman with cancer, was depressed by SCID criteria. She received treatment for depression with a psychostimulant after completion of the survey, was subsequently enrolled in a hospice, and was documented by a psychiatrist to have a remission in her depression before her death. She received the prescription when she was depressed, and she reported that depression somewhat influenced her decision to pursue aid in dying.

DISCUSSION
Among patients who requested a physician’s aid in dying, one in four had clinical depression. However, more than three quarters of people who actually received prescriptions for lethal drugs did not have a depressive disorder. Our findings also indicate that the current practice of legalised aid in dying may allow some potentially ineligible patients to receive a prescription for a lethal drug; two of those who ultimately died by lethal ingestion had depression at the time they received a prescription for a lethal drug and died by ingesting the drug. A third patient was depressed at the time that she requested a physician’s aid in dying and probably received her prescription; she was successfully treated for her depression before she died by lethal ingestion.

Strengths and limitations
Although many investigators have examined the degree to which depression is associated with a desire to die among terminally ill patients,20 we believe that our study is the first to use standardised measures to examine the prevalence and severity of depression and anxiety in a group of patients who have actually requested and are potentially eligible to receive aid in dying.

The strengths of our study include a standard measure of depression (SCID) and a blinding system that controlled for the effect on the ultimate psychiatric diagnosis of the psychiatrist knowing that the patient had requested a physician’s aid in dying. The other measures of depression and anxiety are commonly

Table 1 | Comparison of deceased participants who received and did not receive prescription for lethal drug. Values are mean (SD) unless stated otherwise

<table>
<thead>
<tr>
<th>Measure</th>
<th>Received prescription (n=18)</th>
<th>Did not receive prescription (n=22)</th>
<th>P value (# test)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital anxiety and depression scale—anxiety*</td>
<td>4.8 (3.2)</td>
<td>7.0 (5.1)</td>
<td>0.12</td>
</tr>
<tr>
<td>Hospital anxiety and depression scale—depression†</td>
<td>5.7 (3.4)</td>
<td>7.3 (4.4)</td>
<td>0.19</td>
</tr>
<tr>
<td>Hospital anxiety and depression scale—total†</td>
<td>10.5 (5.0)</td>
<td>14.3 (8.6)</td>
<td>0.10</td>
</tr>
<tr>
<td>Beck hopelessness scale§</td>
<td>5.0 (3.0)</td>
<td>7.5 (5.4)</td>
<td>0.08</td>
</tr>
<tr>
<td>Desire to die¶</td>
<td>1.5 (2.6)</td>
<td>4.7 (3.7)</td>
<td>0.004</td>
</tr>
<tr>
<td>Suffering**</td>
<td>3.7 (2.7)</td>
<td>4.5 (2.9)</td>
<td>0.36</td>
</tr>
<tr>
<td>Quality of life††</td>
<td>4.0 (1.8)</td>
<td>5.1 (2.9)</td>
<td>0.13</td>
</tr>
</tbody>
</table>

*Scores range from 0 (no anxiety) to 21 (severe anxiety).**
†Scores range from 0 (no depression) to 21 (severe depression).††
‡Sum of anxiety and depression scales.‡‡
§Scores range from 0 (not hopeless) to 20 (very hopeless)."'
¶11 point scale: 0=desire to live as long as possible; 10=have a strong desire to die soon.
**11 point scale: 0=have not suffered in the past two weeks; 10=have suffered severely in the past two weeks.
††11 point scale: 0=quality of life in past two weeks is as good as it can be; 10=quality of life in past two weeks is terrible, very bad.
Table 2 | Measures of psychological distress in depressed participants who received a physician’s aid in dying

<table>
<thead>
<tr>
<th>Measure</th>
<th>Case A</th>
<th>Case B</th>
<th>Case C</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCID depression*</td>
<td>–</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Hospital anxiety and depression scale—anxiety†</td>
<td>7</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>Hospital anxiety and depression scale—depression‡</td>
<td>12</td>
<td>10</td>
<td>9</td>
</tr>
<tr>
<td>Hospital anxiety and depression scale—total§</td>
<td>19</td>
<td>14</td>
<td>17</td>
</tr>
<tr>
<td>Beck hopelessness scale¶</td>
<td>9</td>
<td>NA</td>
<td>9</td>
</tr>
<tr>
<td>Desire to die**</td>
<td>6</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>Suffering††</td>
<td>4</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>How much depressed mood influenced decision†‡</td>
<td>1</td>
<td>1</td>
<td>3</td>
</tr>
</tbody>
</table>

NA=not available; SCID=structured clinical interview for American Psychiatric Association Diagnostic and Statistical Manual-IV

*† indicates major depressive disorder present; † indicates major depressive disorder absent.31
†Scores range from 0 (no anxiety) to 21 (severe anxiety).36
‡Scores range from 0 (no depression) to 21 (severe depression).24
§Sum of anxiety and depression subscales.24
¶Scores range from 0 (not hopeless) to 20 (very hopeless).28 Case B declined to complete this scale.
**11 point scale: 0=I desire to live as long as possible; 10=I have a strong desire to die soon.
††11 point scale: 0=I have not suffered in the past two weeks; 10=I have suffered severely in the past two weeks.33

How much depressed mood not at all important in decision to request prescription; 5=depressed mood very important in decision to request prescription.

used and well validated in terminally ill patients. Our study has several limitations. Use of an inclusive approach to categorise somatic symptoms, which, if present, were attributed to depression and not to terminal disease, carries the risk of inflating the prevalence of depressive disorder. In addition, only 28% of invited patients who requested aid in dying agreed to participate; uncertainty exists about the degree to which our data are generalisable to the entire population of patients who request physicians’ aid in dying. In a study of Oregon physicians who reported on 141 requests for aid in dying, only 36% of patients were in a hospice at the time of the request—similarly, only a third of our participants were yet enrolled in a hospice.34 In contrast, data collected by the Oregon Department of Human Services indicates that 80% of patients who die by prescription of a lethal drug are enrolled in a hospice before death.1 This suggests that most patients begin inquiring about a physician’s aid in dying before they enrol in a hospice. Our finding of a low proportion in hospice enrollees reflects this fact, rather than differences between our sample and all Oregonians who die by legal lethal ingestion.

The possibility remains that the three depressed patients who died by lethal ingestion satisfied the requirements of the Death with Dignity Act if the attending physician determined that depression was present but not influencing their judgment. The study participants themselves were divided in whether to attribute their interest in aid in dying to low mood. Although diagnosing depression can be relatively straightforward, determining its role in influencing decision making is more difficult, even by expert assessment. For example, in a study of 321 psychiatrists in Oregon only 6% were very confident that in a single evaluation they could adequately determine whether a psychiatric disorder was impairing the judgment of a patient requesting assisted suicide.35 In a study of 290 US forensic psychiatrists, 58% indicated that the presence of major depressive disorder should result in an automatic finding of incompetence for the purposes of obtaining assisted suicide.36 These data support that of the two components of the mental health assessment—presence of a disorder and determination of its influence—the greatest weight in determining eligibility for aid in dying should be on whether a relevant mental disorder such as depression can be diagnosed.

Depression and desire for death

Other studies and surveys from Oregon have indicated that aid in dying among depressed patients is very rare. Physicians in Oregon who received requests for aid in dying from 143 patients after enactment of the Death with Dignity Act reported that 20% were depressed—a proportion comparable to what we found in this study. None of the depressed patients on whom they submitted information received a prescription for a lethal drug.24 Studies of healthcare providers, including hospice professionals, and family members in Oregon indicate that they believe that depression was rarely a factor influencing requests for a physician’s aid in dying.15-17 Our study suggests that in some cases depression is missed or overlooked.

In contrast, studies of interest in euthanasia from populations outside of Oregon suggest that depression and psychosocial distress are prominent among patients who endorse an interest in hastened death. For example, in a study of 200 terminally ill inpatients with cancer, the prevalence of depressive syndromes was 59% among patients with a serious and pervasive desire to die but only 8% among patients without such a desire.4 In a study of 988 terminally ill patients living in areas where physicians’ aid in dying was not legal, 10.6% reported seriously considering euthanasia or a physician’s aid in dying for themselves, and those with depressive symptoms were 25% more likely to endorse this.9 In a study of 98 patients admitted to a palliative care inpatient setting in the northeast United States, patients with major depression were four times more likely to have a high desire for hastened death.9

Whether findings from these patient groups can be extrapolated to patients who have actively requested legal physicians’ aid in dying has remained uncertain—although 17% of Oregonians are potentially interested in aid in dying, only 1-2% actually request it.34,37 For example, in a study of 161 patients with cancer in Oregon who were longitudinally examined for interest in a physician’s aid in dying, 19 had a serious interest in aid in dying, fewer than half with a serious interest discussed aid in dying with their physician, two requested a prescription for a lethal drug, and none received one.26 This suggests that most terminally ill patients who declare interest in aid in dying do not actively pursue aid in dying under legalised conditions. As such, studies of preferences for aid in dying in these groups may misrepresent actual requesters of aid in dying. In contrast, our surveyed participants had taken active steps to pursue a physician’s aid in dying in one of the few jurisdictions where it is legal—all either
Among terminally ill Oregonians who participated in our study and received a prescription for a lethal drug, one in six had clinical depression explicitly requested aid in dying from a physician or contacted Compassion and Choices for information on the Oregon Death with Dignity Act. Before death, almost half had obtained a prescription for a lethal drug under the law.

Conclusions
Our study suggests that most patients who request aid in dying do not have a depressive disorder. However, the current practice of the Death with Dignity Act in Oregon may not adequately protect all mentally ill patients, and increased vigilance and systematic examination for depression among patients who may access legalised aid in dying are needed. Tools for screening for depression such as those used in our study are easy to administer and may help to determine which patients need further evaluation by a mental health professional. Further study is needed to determine the effect of treatment of depression on the choice to hasten death.

Contributors:
LG participated in the design, receipt of funding, data analysis, and manuscript preparation. ERG participated in the design, data gathering, and manuscript preparation. SKD participated in the design, data analysis, and manuscript preparation. All authors saw and approved the final version. LG is the guarantor.

Funding: Northwest Health Foundation. The funding source had no role in any aspect of the study or this paper.

Competing interests: None declared.

Ethical approval: The study was approved by the institutional review board of the Portland Veterans Affairs Medical Center and the participating medical centres.

Provenance and peer review: Not commissioned; externally peer reviewed.

The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs.